JP6415545B2 - 抑うつ障害の治療用及び/又は予防用の新規薬剤 - Google Patents

抑うつ障害の治療用及び/又は予防用の新規薬剤 Download PDF

Info

Publication number
JP6415545B2
JP6415545B2 JP2016516184A JP2016516184A JP6415545B2 JP 6415545 B2 JP6415545 B2 JP 6415545B2 JP 2016516184 A JP2016516184 A JP 2016516184A JP 2016516184 A JP2016516184 A JP 2016516184A JP 6415545 B2 JP6415545 B2 JP 6415545B2
Authority
JP
Japan
Prior art keywords
depression
treatment
compound
group
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016516184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520112A (ja
JP2016520112A5 (cg-RX-API-DMAC7.html
Inventor
ベノリエル,ジャン−ジャック
ベッカー,クリステル
ブヴィエ,エロディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Université Paris Descartes
Sorbonne Université
Original Assignee
Assistance Publique - Hôpitaux de Paris
Université Paris Descartes
Sorbonne Université
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Université Paris Descartes, Sorbonne Université filed Critical Assistance Publique - Hôpitaux de Paris
Publication of JP2016520112A publication Critical patent/JP2016520112A/ja
Publication of JP2016520112A5 publication Critical patent/JP2016520112A5/ja
Application granted granted Critical
Publication of JP6415545B2 publication Critical patent/JP6415545B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016516184A 2013-05-30 2014-05-30 抑うつ障害の治療用及び/又は予防用の新規薬剤 Expired - Fee Related JP6415545B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13169936.5 2013-05-30
EP13169936.5A EP2808023A1 (en) 2013-05-30 2013-05-30 New drug for the treatment and/or prevention of depressive disorders
PCT/EP2014/061240 WO2014191547A1 (en) 2013-05-30 2014-05-30 New drug for the treatment and/or prevention of depressive disorders

Publications (3)

Publication Number Publication Date
JP2016520112A JP2016520112A (ja) 2016-07-11
JP2016520112A5 JP2016520112A5 (cg-RX-API-DMAC7.html) 2017-04-20
JP6415545B2 true JP6415545B2 (ja) 2018-10-31

Family

ID=48520808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016516184A Expired - Fee Related JP6415545B2 (ja) 2013-05-30 2014-05-30 抑うつ障害の治療用及び/又は予防用の新規薬剤

Country Status (5)

Country Link
US (2) US20160067231A1 (cg-RX-API-DMAC7.html)
EP (2) EP2808023A1 (cg-RX-API-DMAC7.html)
JP (1) JP6415545B2 (cg-RX-API-DMAC7.html)
CA (1) CA2910530A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014191547A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6715568B2 (ja) * 2015-01-22 2020-07-01 公益財団法人東京都医学総合研究所 睡眠異常をきたすうつ病のモデル動物
AU2018371628B2 (en) * 2017-11-22 2021-08-12 Excelsior Pharmatech Labs Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
CN116870180B (zh) * 2023-08-08 2026-04-21 中南大学湘雅医院 一种递送神经递质的纳米制剂及其制备方法与应用
CN117904008B (zh) * 2024-03-19 2024-06-11 山东中科嘉亿生物工程有限公司 一种预防和缓解抑郁的戊糖片球菌jypr-9187及其菌剂和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1243101A (en) * 1999-10-28 2001-05-08 Cary Pharmaceuticals Inc. High dose folic acid for the treatment of hyperhomocysteinemia
US7758872B1 (en) * 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
SI1631557T1 (sl) * 2003-06-12 2007-06-30 Btg Int Ltd Cikličen hidroksilamin kot psihoaktivne spojine
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
US8778969B2 (en) 2009-11-07 2014-07-15 Peter H Proctor Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines

Also Published As

Publication number Publication date
US20190060298A1 (en) 2019-02-28
WO2014191547A1 (en) 2014-12-04
CA2910530A1 (en) 2014-12-04
EP3003308B1 (en) 2020-09-30
EP3003308A1 (en) 2016-04-13
EP2808023A1 (en) 2014-12-03
JP2016520112A (ja) 2016-07-11
US20160067231A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
US12036190B2 (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
Gasse et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis
Alda Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics
Okur et al. Long‐term NAD+ supplementation prevents the progression of age‐related hearing loss in mice
JP6854766B2 (ja) チロシンキナーゼ阻害剤を用いる組成物および方法
Geekiyanage et al. Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease
US20190060298A1 (en) New drug for the treatment and/or prevention of depressive disorders
AU2005227420A1 (en) Method and compositions for altering cell function
Zhao et al. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance‐associated promotion of Alzheimer's disease β‐amyloid neuropathology
Sun et al. DR region of NKAα1 is a target to ameliorate hepatic lipid metabolism disturbance in obese mice
CN105008394A (zh) 治疗结肠直肠癌的方法
JP2011503164A (ja) 呼吸障害に関連する方法
Liang et al. Ginkgo biloba extract 50 (GBE50) exerts antifibrotic and antioxidant effects on pulmonary fibrosis in mice by regulating Nrf2 and TGF-β1/Smad pathways
Singh et al. Vascular and immunopathological role of asymmetric dimethylarginine (ADMA) in experimental autoimmune encephalomyelitis
Tang et al. Human tissue kallikrein 1 ameliorates erectile function via modulation of macroautophagy in aged transgenic rats
JP2025534979A (ja) 神経変性疾患に関連する神経変性を減少させる方法
JP5788907B2 (ja) 疾患の治療に使用される化合物
US11857531B2 (en) Combination mast cell inhibition for treatment of BPH/LUTS
US20200230115A1 (en) Methods of treating influenza-associated viral pneumonia
He et al. BNTA attenuates temporomandibular joint osteoarthritis progression by directly targeting ALDH3A1: an in vivo and in vitro study
US20100247679A1 (en) Methods and compositions for altering cell function
US20070155687A1 (en) Methods and compositions for altering cell function
Erdogan et al. Assessing the nitric oxide and asymmetric dimethylarginine levels in lifelong premature ejaculation: A prospective study
JP5362747B2 (ja) アルツハイマー病の治療用医薬品の調製のためのs−アデノシルメチオニン(sam)およびスーパーオキシドジスムターゼ(sod)の使用
Zhang et al. Adiponectin targets the AMPK/mTOR signaling pathway to alleviate cognitive impairment in epilepsy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180228

TRDD Decision of grant or rejection written
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20180808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180808

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181002

R150 Certificate of patent or registration of utility model

Ref document number: 6415545

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees